About
Nanosynex is developing solutions designed to improve testing quality and reduce healthcare costs by accelerating diagnostic processes.
Nanosynex is focused on the development and commercialization of an innovative antimicrobial susceptibility test (AST). The technology is based on a purely phenotypic approach and uses a microfluidic disposable test cartridge platform and method that optimizes bacterial growth.
The Nanosynex solution comprises a disposable test platform, hardware, and analysis software. The product will allow laboratories to perform and provide results for same-day antimicrobial susceptibility tests, enabling doctors to create targeted, personalized antibiotic prescriptions for their patients.
The companys technology stems from research discoveries made in the lab of Professor Shulamit Levenberg, dean of the Faculty of Biomedical Engineering at the Technion.
Funding history · 3 rounds · $6.3M total
Company Intelligence Q&A
Structured intelligence from startupim data — optimized for AI retrieval and grounding.
- What is Nanosynex's primary focus in healthcare technology?
- Nanosynex is focused on developing and commercializing an innovative antimicrobial susceptibility test (AST) to improve testing quality and reduce healthcare costs by accelerating diagnostic processes.
- When was Nanosynex founded and where is its headquarters located?
- Nanosynex was founded in February 2017 and is headquartered in Tel Aviv-Yafo, Israel.
- What is the core technology behind Nanosynex's antimicrobial susceptibility test?
- Nanosynex's technology is based on a phenotypic approach using a microfluidic disposable test cartridge platform and method that optimizes bacterial growth.
- What is the total amount of funding Nanosynex has raised to date?
- Nanosynex has raised a total of $6,340,000 USD across various funding rounds.
- Which institution's research discoveries form the basis of Nanosynex's technology?
- Nanosynex's technology stems from research discoveries made in the lab of Professor Shulamit Levenberg, dean of the Faculty of Biomedical Engineering at the Technion.
- When did Nanosynex receive its most recent grant from the IIA?
- Nanosynex received a grant of $40,000 USD from the IIA in June 2025.
- What is Nanosynex's current employee count?
- Nanosynex currently has 8 employees.
- What is Nanosynex's product stage?
- Nanosynex's product is currently in the R&D stage.
- When did Nanosynex complete its most recent funding round?
- Nanosynex completed an undisclosed funding round of $500,000 USD in January 2025.